Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform

TY - JOUR

T1 - Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform

AU - Maier, Daniel

AU - Vehreschild, Jörg Janne

AU - Uhl, Barbara

AU - Meyer, Sandra

AU - Berger-Thürmel, Karin

AU - Boerries, Melanie

AU - Braren, Rickmer

AU - Grünwald, Viktor

AU - Hadaschik, Boris

AU - Palm, Stefan

AU - Singer, Susanne

AU - Stuschke, Martin

AU - Juárez, David

AU - Delpy, Pierre

AU - Lambarki, Mohamed

AU - Hummel, Michael

AU - Engels, Cäcilia

AU - Andreas, Stefanie

AU - Gökbuget, Nicola

AU - Ihrig, Kristina

AU - Burock, Susen

AU - Keune, Dietmar

AU - Eggert, Angelika

AU - Keilholz, Ulrich

AU - Schulz, Hagen

AU - Büttner, Daniel

AU - Löck, Steffen

AU - Krause, Mechthild

AU - Esins, Mirko

AU - Ressing, Frank

AU - Schuler, Martin

AU - Brandts, Christian

AU - Brucker, Daniel P

AU - Husmann, Gabriele

AU - Oellerich, Thomas

AU - Metzger, Patrick

AU - Voigt, Frederik

AU - Illert, Anna L

AU - Theobald, Matthias

AU - Kindler, Thomas

AU - Sudhof, Ursula

AU - Reckmann, Achim

AU - Schwinghammer, Felix

AU - Nasseh, Daniel

AU - Weichert, Wilko

AU - von Bergwelt-Baildon, Michael

AU - Bitzer, Michael

AU - Malek, Nisar

AU - Öner, Öznur

AU - Schulze-Osthoff, Klaus

AU - Bartels, Stefan

AU - Haier, Jörg

AU - Ammann, Raimund

AU - Schmidt, Anja Franziska

AU - Guenther, Bernd

AU - Janning, Melanie

AU - Kasper, Bernd

AU - Loges, Sonja

AU - Stilgenbauer, Stephan

AU - Kuhn, Peter

AU - Tausch, Eugen

AU - Runow, Silvana

AU - Kerscher, Alexander

AU - Neumann, Michael

AU - Breu, Martin

AU - Lablans, Martin

AU - Serve, Hubert

N1 - © 2023. The Author(s).

PY - 2023/5

Y1 - 2023/5

N2 - Treatment concepts in oncology are becoming increasingly personalized and diverse. Successively, changes in standards of care mandate continuous monitoring of patient pathways and clinical outcomes based on large, representative real-world data. The German Cancer Consortium's (DKTK) Clinical Communication Platform (CCP) provides such opportunity. Connecting fourteen university hospital-based cancer centers, the CCP relies on a federated IT-infrastructure sourcing data from facility-based cancer registry units and biobanks. Federated analyses resulted in a cohort of 600,915 patients, out of which 232,991 were incident since 2013 and for which a comprehensive documentation is available. Next to demographic data (i.e., age at diagnosis: 2.0% 0-20 years, 8.3% 21-40 years, 30.9% 41-60 years, 50.1% 61-80 years, 8.8% 81+ years; and gender: 45.2% female, 54.7% male, 0.1% other) and diagnoses (five most frequent tumor origins: 22,523 prostate, 18,409 breast, 15,575 lung, 13,964 skin/malignant melanoma, 9005 brain), the cohort dataset contains information about therapeutic interventions and response assessments and is connected to 287,883 liquid and tissue biosamples. Focusing on diagnoses and therapy-sequences, showcase analyses of diagnosis-specific sub-cohorts (pancreas, larynx, kidney, thyroid gland) demonstrate the analytical opportunities offered by the cohort's data. Due to its data granularity and size, the cohort is a potential catalyst for translational cancer research. It provides rapid access to comprehensive patient groups and may improve the understanding of the clinical course of various (even rare) malignancies. Therefore, the cohort may serve as a decisions-making tool for clinical trial design and contributes to the evaluation of scientific findings under real-world conditions.

AB - Treatment concepts in oncology are becoming increasingly personalized and diverse. Successively, changes in standards of care mandate continuous monitoring of patient pathways and clinical outcomes based on large, representative real-world data. The German Cancer Consortium's (DKTK) Clinical Communication Platform (CCP) provides such opportunity. Connecting fourteen university hospital-based cancer centers, the CCP relies on a federated IT-infrastructure sourcing data from facility-based cancer registry units and biobanks. Federated analyses resulted in a cohort of 600,915 patients, out of which 232,991 were incident since 2013 and for which a comprehensive documentation is available. Next to demographic data (i.e., age at diagnosis: 2.0% 0-20 years, 8.3% 21-40 years, 30.9% 41-60 years, 50.1% 61-80 years, 8.8% 81+ years; and gender: 45.2% female, 54.7% male, 0.1% other) and diagnoses (five most frequent tumor origins: 22,523 prostate, 18,409 breast, 15,575 lung, 13,964 skin/malignant melanoma, 9005 brain), the cohort dataset contains information about therapeutic interventions and response assessments and is connected to 287,883 liquid and tissue biosamples. Focusing on diagnoses and therapy-sequences, showcase analyses of diagnosis-specific sub-cohorts (pancreas, larynx, kidney, thyroid gland) demonstrate the analytical opportunities offered by the cohort's data. Due to its data granularity and size, the cohort is a potential catalyst for translational cancer research. It provides rapid access to comprehensive patient groups and may improve the understanding of the clinical course of various (even rare) malignancies. Therefore, the cohort may serve as a decisions-making tool for clinical trial design and contributes to the evaluation of scientific findings under real-world conditions.

KW - Adolescent

KW - Adult

KW - Child

KW - Child, Preschool

KW - Female

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - Male

KW - Young Adult

KW - Neoplasms/diagnosis

KW - Middle Aged

KW - Aged

KW - Aged, 80 and over

KW - Cohort Studies

U2 - 10.1007/s10654-023-00990-w

DO - 10.1007/s10654-023-00990-w

M3 - SCORING: Journal article

C2 - 37017830

VL - 38

SP - 573

EP - 586

JO - EUR J EPIDEMIOL

JF - EUR J EPIDEMIOL

SN - 0393-2990

IS - 5

ER -